thecardiologyadvisor.com20h
AHA: Variation Seen in Rates of SGLT2i Rx for Heart Failure, LVEF Higher Than 40%
From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular ejection fraction (LVEF) ...
thecardiologyadvisor.com20h
GLP-1RA Drugs, SGLT2 Inhibitors Prevent Liver Disease in T2D
GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.
thecardiologyadvisor.com20h
2018 to 2020 Saw Rise in Firearm Injury-Related Emergency Department Visits
Firearm injury-related emergency department visit rates increased from 2018 to 2020, then decreased through 2023.
thecardiologyadvisor.com20h
Exposures to 8 Factors Contribute to Increasing Trends in IHD, Stroke
Altered exposures to eight factors contribute to increasing trends in ischemic heart disease (IHD) and stroke on a global scale.
thecardiologyadvisor.com20h
In COVID-19, Inborn Errors of Immunity Increase Risk for Hospital, ICU Admission
Hospital and ICU admission rates within 30 days after COVID-19 infection were greater in patients with inborn errors of immunity (IEI).
thecardiologyadvisor.com20h
Finerenone Plus SGLT2i in Heart Failure Adds Protection for Cardiovascular Events
SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.
thecardiologyadvisor.com20h
Heart Failure With Preserved Ejection Fraction Underdiagnosed
Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR).